NAMS Menopause Certification Professional Review
Updated 2026 | 300+ Practice Questions & Verified
Answers | Comprehensive Menopause Society
Certification Study Guide, Advanced Women's
Health Exam Prep, Perimenopause &
Postmenopause, Hormone Therapy, Vasomotor
Symptoms, Genitourinary Syndrome of Menopause
(GSM), Bone Health, Cardiovascular Risk, Sexual
Health, Evidence-Based Clinical Practice, Detailed
Rationales
Question 1: A 52-year-old woman reports that her menstrual periods have
become irregular over the past year, with cycles varying from 21 to 45 days.
She has also noticed occasional hot flashes. According to the STRAW+10
staging system, which stage best describes her current reproductive aging
status?
A. Early perimenopause
B. Late perimenopause
C. Early postmenopause
D. Late reproductive stage
CORRECT ANSWER: A. Early perimenopause
Rationale: The STRAW+10 criteria define early perimenopause (Stage -2) as beginning
with the onset of persistent (7+ days) differences in menstrual cycle length. The
hallmark is variation in cycle length of 7 days or more in consecutive cycles, which this
patient is experiencing. Late perimenopause (Stage -1) is characterized by 60 or more
days of amenorrhea. Early postmenopause (Stage +1) is defined as the first 5 years after
the final menstrual period.
Question 2: A patient is concerned about the cardiovascular risks associated
with hormone therapy. Which of the following statements about the timing of
hormone therapy initiation and cardiovascular risk is most accurate based on
the "timing hypothesis"?
A. Hormone therapy should be avoided in all women over 60 due to increased risk of
myocardial infarction.
B. Initiating hormone therapy within 10 years of menopause onset reduces coronary
heart disease risk compared to late initiation.
C. The risk of venous thromboembolism is lower when hormone therapy is started more
than 20 years after menopause.
D. Oral estrogen is associated with a lower risk of cardiovascular events compared to
transdermal estrogen in all age groups.
,CORRECT ANSWER: B. Initiating hormone therapy within 10 years of
menopause onset reduces coronary heart disease risk compared to late
initiation.
Rationale: The "timing hypothesis" suggests that the cardiovascular effects of hormone
therapy (HT) depend on the timing of initiation relative to menopause. Early initiation
(within 10 years of menopause or before age 60) is associated with a reduced risk of
coronary heart disease, while late initiation (more than 10-20 years after menopause)
may increase risk due to pre-existing atherosclerotic plaque vulnerability. This principle
is supported by secondary analyses of the WHI and other observational studies.
Question 3: Which of the following is the primary mechanism by which
estradiol exerts its effects on the hypothalamic-pituitary-ovarian axis to
regulate gonadotropin secretion in a perimenopausal woman?
A. Estradiol binds to G-protein coupled receptors on kisspeptin neurons, increasing
GnRH pulse frequency.
B. Estradiol inhibits GnRH secretion via classical nuclear receptor signaling to reduce
LH and FSH synthesis.
C. Estradiol has a direct inhibitory effect on the anterior pituitary, decreasing its
sensitivity to GnRH.
D. Estradiol increases the synthesis of inhibin B, which selectively suppresses FSH
production.
CORRECT ANSWER: B. Estradiol inhibits GnRH secretion via classical nuclear
receptor signaling to reduce LH and FSH synthesis.
Rationale: Estradiol primarily exerts negative feedback on the hypothalamus via
estrogen receptor-alpha (ERα) signaling in kisspeptin neurons. This signaling inhibits the
release of GnRH from the hypothalamus, which in turn reduces the synthesis and
release of LH and FSH from the anterior pituitary. As estradiol levels decline in
perimenopause, this negative feedback is reduced, leading to elevated gonadotropin
levels.
Question 4: A 48-year-old woman presents with heavy menstrual bleeding. She
has a body mass index (BMI) of 34 kg/m². Which of the following is a critical
first-line diagnostic step to rule out endometrial pathology before initiating
hormone therapy?
A. Serum CA-125 level
B. Endometrial biopsy
C. Transvaginal ultrasound to measure endometrial thickness
D. Hysteroscopy with direct visualization
CORRECT ANSWER: C. Transvaginal ultrasound to measure endometrial
thickness
Rationale: In a woman with abnormal uterine bleeding (AUB), particularly in the
perimenopausal period and with obesity (a risk factor for endometrial hyperplasia), the
,first-line diagnostic step is a transvaginal ultrasound to measure the endometrial stripe
thickness. An endometrial thickness of ≤4-5 mm generally has a high negative predictive
value for endometrial pathology. An endometrial biopsy is indicated if the stripe is
thickened or if other risk factors are present.
Question 5: Which of the following changes in the vaginal microbiome is most
characteristic of the menopausal transition?
A. Increased Lactobacillus crispatus dominance with a decrease in pH.
B. Decreased microbial diversity and a shift toward a more Escherichia coli-rich
environment.
C. A significant increase in Lactobacillus iners with an acidic pH.
D. Loss of protective Lactobacillus species and an increase in microbial diversity with a
rise in pH.
CORRECT ANSWER: D. Loss of protective Lactobacillus species and an
increase in microbial diversity with a rise in pH.
Rationale: With the loss of estrogen, vaginal glycogen content decreases, which reduces
the substrate for Lactobacillus species. This leads to a decline in Lactobacillus
dominance, an increase in overall microbial diversity (including more pathogenic
anaerobes), and an increase in vaginal pH (typically >4.5). This dysbiosis predisposes to
genitourinary syndrome of menopause (GSM) and increased infection risk.
Question 6: A 55-year-old woman on oral conjugated equine estrogens (CEE)
and medroxyprogesterone acetate (MPA) for menopausal symptoms develops a
new onset of mild hypertension. Which of the following is the most
appropriate management strategy?
A. Discontinue hormone therapy immediately.
B. Switch to a lower dose of the same oral regimen.
C. Consider switching to a transdermal estradiol patch.
D. Add a thiazide diuretic as first-line therapy.
CORRECT ANSWER: C. Consider switching to a transdermal estradiol patch.
Rationale: Oral estrogen therapy is associated with a small but significant increase in
blood pressure (BP) in some women, likely due to the first-pass hepatic effect
stimulating the renin-angiotensin-aldosterone system (RAAS). Transdermal estradiol
bypasses the hepatic first-pass effect and is not associated with the same increases in
BP, making it a suitable alternative for a woman who develops hypertension on oral
therapy.
Question 7: Which of the following best describes the role of follicle-
stimulating hormone (FSH) in the diagnosis of menopause?
A. A single FSH level > 30 mIU/mL is diagnostic of menopause in all women.
B. FSH levels should be measured on day 3 of the menstrual cycle for accurate
menopausal diagnosis.
, C. Elevated FSH levels are diagnostic of menopause even in the presence of estrogen-
containing intrauterine devices.
D. An FSH level > 25 mIU/mL, combined with amenorrhea for 12 months, is sufficient
for diagnosis in a woman over 45.
CORRECT ANSWER: D. An FSH level > 25 mIU/mL, combined with
amenorrhea for 12 months, is sufficient for diagnosis in a woman over 45.
Rationale: While a diagnosis of menopause is primarily clinical (12 months of
amenorrhea), laboratory confirmation is sometimes used. For women over 45, an
elevated FSH level (generally >25-30 mIU/mL) combined with 12 months of
amenorrhea is considered sufficient for diagnosis. FSH should not be measured in
women using hormonal contraceptives or hormone therapy, as these will suppress FSH
levels.
Question 8: A 59-year-old woman with a history of breast cancer (ER+/PR+,
treated with tamoxifen) is seeking relief from severe vasomotor symptoms.
Which of the following is considered the most appropriate non-hormonal
pharmacological option?
A. Gabapentin
B. Black cohosh
C. Soy isoflavones
D. Paroxetine
CORRECT ANSWER: D. Paroxetine
Rationale: For women with a history of breast cancer, systemic hormone therapy is
contraindicated. Among non-hormonal options, paroxetine (specifically the low-dose
formulation Brisdelle) is FDA-approved for the treatment of moderate-to-severe
vasomotor symptoms. SNRIs (venlafaxine, desvenlafaxine), gabapentin, and other SSRIs
are also used, but paroxetine is often preferred due to its approval and efficacy. Caution
is needed with tamoxifen due to CYP2D6 interaction, but it is not an absolute
contraindication.
Question 9: What is the primary reason that combined continuous hormone
therapy is preferred over sequential therapy for a woman who is 6 years
postmenopausal?
A. Continuous therapy provides better relief of vasomotor symptoms.
B. Continuous therapy is associated with a lower risk of breast cancer.
C. Continuous therapy eliminates the need for a monthly withdrawal bleed.
D. Continuous therapy is more effective for the treatment of sleep disturbances.
CORRECT ANSWER: C. Continuous therapy eliminates the need for a monthly
withdrawal bleed.
Rationale: In a woman who is 6 years postmenopausal (and thus has endometrial
atrophy), combined continuous hormone therapy (estrogen + progestogen daily) is
Updated 2026 | 300+ Practice Questions & Verified
Answers | Comprehensive Menopause Society
Certification Study Guide, Advanced Women's
Health Exam Prep, Perimenopause &
Postmenopause, Hormone Therapy, Vasomotor
Symptoms, Genitourinary Syndrome of Menopause
(GSM), Bone Health, Cardiovascular Risk, Sexual
Health, Evidence-Based Clinical Practice, Detailed
Rationales
Question 1: A 52-year-old woman reports that her menstrual periods have
become irregular over the past year, with cycles varying from 21 to 45 days.
She has also noticed occasional hot flashes. According to the STRAW+10
staging system, which stage best describes her current reproductive aging
status?
A. Early perimenopause
B. Late perimenopause
C. Early postmenopause
D. Late reproductive stage
CORRECT ANSWER: A. Early perimenopause
Rationale: The STRAW+10 criteria define early perimenopause (Stage -2) as beginning
with the onset of persistent (7+ days) differences in menstrual cycle length. The
hallmark is variation in cycle length of 7 days or more in consecutive cycles, which this
patient is experiencing. Late perimenopause (Stage -1) is characterized by 60 or more
days of amenorrhea. Early postmenopause (Stage +1) is defined as the first 5 years after
the final menstrual period.
Question 2: A patient is concerned about the cardiovascular risks associated
with hormone therapy. Which of the following statements about the timing of
hormone therapy initiation and cardiovascular risk is most accurate based on
the "timing hypothesis"?
A. Hormone therapy should be avoided in all women over 60 due to increased risk of
myocardial infarction.
B. Initiating hormone therapy within 10 years of menopause onset reduces coronary
heart disease risk compared to late initiation.
C. The risk of venous thromboembolism is lower when hormone therapy is started more
than 20 years after menopause.
D. Oral estrogen is associated with a lower risk of cardiovascular events compared to
transdermal estrogen in all age groups.
,CORRECT ANSWER: B. Initiating hormone therapy within 10 years of
menopause onset reduces coronary heart disease risk compared to late
initiation.
Rationale: The "timing hypothesis" suggests that the cardiovascular effects of hormone
therapy (HT) depend on the timing of initiation relative to menopause. Early initiation
(within 10 years of menopause or before age 60) is associated with a reduced risk of
coronary heart disease, while late initiation (more than 10-20 years after menopause)
may increase risk due to pre-existing atherosclerotic plaque vulnerability. This principle
is supported by secondary analyses of the WHI and other observational studies.
Question 3: Which of the following is the primary mechanism by which
estradiol exerts its effects on the hypothalamic-pituitary-ovarian axis to
regulate gonadotropin secretion in a perimenopausal woman?
A. Estradiol binds to G-protein coupled receptors on kisspeptin neurons, increasing
GnRH pulse frequency.
B. Estradiol inhibits GnRH secretion via classical nuclear receptor signaling to reduce
LH and FSH synthesis.
C. Estradiol has a direct inhibitory effect on the anterior pituitary, decreasing its
sensitivity to GnRH.
D. Estradiol increases the synthesis of inhibin B, which selectively suppresses FSH
production.
CORRECT ANSWER: B. Estradiol inhibits GnRH secretion via classical nuclear
receptor signaling to reduce LH and FSH synthesis.
Rationale: Estradiol primarily exerts negative feedback on the hypothalamus via
estrogen receptor-alpha (ERα) signaling in kisspeptin neurons. This signaling inhibits the
release of GnRH from the hypothalamus, which in turn reduces the synthesis and
release of LH and FSH from the anterior pituitary. As estradiol levels decline in
perimenopause, this negative feedback is reduced, leading to elevated gonadotropin
levels.
Question 4: A 48-year-old woman presents with heavy menstrual bleeding. She
has a body mass index (BMI) of 34 kg/m². Which of the following is a critical
first-line diagnostic step to rule out endometrial pathology before initiating
hormone therapy?
A. Serum CA-125 level
B. Endometrial biopsy
C. Transvaginal ultrasound to measure endometrial thickness
D. Hysteroscopy with direct visualization
CORRECT ANSWER: C. Transvaginal ultrasound to measure endometrial
thickness
Rationale: In a woman with abnormal uterine bleeding (AUB), particularly in the
perimenopausal period and with obesity (a risk factor for endometrial hyperplasia), the
,first-line diagnostic step is a transvaginal ultrasound to measure the endometrial stripe
thickness. An endometrial thickness of ≤4-5 mm generally has a high negative predictive
value for endometrial pathology. An endometrial biopsy is indicated if the stripe is
thickened or if other risk factors are present.
Question 5: Which of the following changes in the vaginal microbiome is most
characteristic of the menopausal transition?
A. Increased Lactobacillus crispatus dominance with a decrease in pH.
B. Decreased microbial diversity and a shift toward a more Escherichia coli-rich
environment.
C. A significant increase in Lactobacillus iners with an acidic pH.
D. Loss of protective Lactobacillus species and an increase in microbial diversity with a
rise in pH.
CORRECT ANSWER: D. Loss of protective Lactobacillus species and an
increase in microbial diversity with a rise in pH.
Rationale: With the loss of estrogen, vaginal glycogen content decreases, which reduces
the substrate for Lactobacillus species. This leads to a decline in Lactobacillus
dominance, an increase in overall microbial diversity (including more pathogenic
anaerobes), and an increase in vaginal pH (typically >4.5). This dysbiosis predisposes to
genitourinary syndrome of menopause (GSM) and increased infection risk.
Question 6: A 55-year-old woman on oral conjugated equine estrogens (CEE)
and medroxyprogesterone acetate (MPA) for menopausal symptoms develops a
new onset of mild hypertension. Which of the following is the most
appropriate management strategy?
A. Discontinue hormone therapy immediately.
B. Switch to a lower dose of the same oral regimen.
C. Consider switching to a transdermal estradiol patch.
D. Add a thiazide diuretic as first-line therapy.
CORRECT ANSWER: C. Consider switching to a transdermal estradiol patch.
Rationale: Oral estrogen therapy is associated with a small but significant increase in
blood pressure (BP) in some women, likely due to the first-pass hepatic effect
stimulating the renin-angiotensin-aldosterone system (RAAS). Transdermal estradiol
bypasses the hepatic first-pass effect and is not associated with the same increases in
BP, making it a suitable alternative for a woman who develops hypertension on oral
therapy.
Question 7: Which of the following best describes the role of follicle-
stimulating hormone (FSH) in the diagnosis of menopause?
A. A single FSH level > 30 mIU/mL is diagnostic of menopause in all women.
B. FSH levels should be measured on day 3 of the menstrual cycle for accurate
menopausal diagnosis.
, C. Elevated FSH levels are diagnostic of menopause even in the presence of estrogen-
containing intrauterine devices.
D. An FSH level > 25 mIU/mL, combined with amenorrhea for 12 months, is sufficient
for diagnosis in a woman over 45.
CORRECT ANSWER: D. An FSH level > 25 mIU/mL, combined with
amenorrhea for 12 months, is sufficient for diagnosis in a woman over 45.
Rationale: While a diagnosis of menopause is primarily clinical (12 months of
amenorrhea), laboratory confirmation is sometimes used. For women over 45, an
elevated FSH level (generally >25-30 mIU/mL) combined with 12 months of
amenorrhea is considered sufficient for diagnosis. FSH should not be measured in
women using hormonal contraceptives or hormone therapy, as these will suppress FSH
levels.
Question 8: A 59-year-old woman with a history of breast cancer (ER+/PR+,
treated with tamoxifen) is seeking relief from severe vasomotor symptoms.
Which of the following is considered the most appropriate non-hormonal
pharmacological option?
A. Gabapentin
B. Black cohosh
C. Soy isoflavones
D. Paroxetine
CORRECT ANSWER: D. Paroxetine
Rationale: For women with a history of breast cancer, systemic hormone therapy is
contraindicated. Among non-hormonal options, paroxetine (specifically the low-dose
formulation Brisdelle) is FDA-approved for the treatment of moderate-to-severe
vasomotor symptoms. SNRIs (venlafaxine, desvenlafaxine), gabapentin, and other SSRIs
are also used, but paroxetine is often preferred due to its approval and efficacy. Caution
is needed with tamoxifen due to CYP2D6 interaction, but it is not an absolute
contraindication.
Question 9: What is the primary reason that combined continuous hormone
therapy is preferred over sequential therapy for a woman who is 6 years
postmenopausal?
A. Continuous therapy provides better relief of vasomotor symptoms.
B. Continuous therapy is associated with a lower risk of breast cancer.
C. Continuous therapy eliminates the need for a monthly withdrawal bleed.
D. Continuous therapy is more effective for the treatment of sleep disturbances.
CORRECT ANSWER: C. Continuous therapy eliminates the need for a monthly
withdrawal bleed.
Rationale: In a woman who is 6 years postmenopausal (and thus has endometrial
atrophy), combined continuous hormone therapy (estrogen + progestogen daily) is
